Prehabilitation Intervention to Maximize Early Recovery (PRIMER) in Liver Transplantation (PRIMER)
Development and Testing of a Prehabilitation Intervention to Maximize Early Recovery (PRIMER) in Liver Transplantation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Perelman Center for Advanced Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must be wait-listed, in transplant evaluation, or "Penn Ready" with a MELD-Na score less than or equal to 25;
- Patients must be English speaking and own/use a smartphone and cognitively able to consent;
- Patient and physician feel that individual can safely participate in an exercise program;
- Meeting at least one 'at risk' criterion for impaired physical performance, frailty, or malnutrition (by SPPB, abPG-SG, dynamometer measured grip strength), or physical deconditioning as determined by physical therapist, or treating clinician.
Exclusion Criteria:
- The patient is unable to provide informed consent;
- The patient has been hospitalized within the last 30 days;
- A score of 0-3 points on the SPPB assessment indicating inability to participate in a physical activity program or a score of 12 in the absence of frailty or malnutrition (indicating low risk for poor physical or performance or malnutrition);
- The patient is at risk for falling as defined by clinician assessment results or if the patient states that he/she has a history of falling (record of a fall(s) in the past 30 days);
- The patient is already enrolled in a financial incentive-based exercise program using a wearable device;
- Any other medical conditions that would prohibit participation in a physical activity program as determined by transplant clinicians or severe vision, hearing, or mobility impairment precluding participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm 1 - Control Arm
Usual care, nutrition and exercise counseling at baseline, use of the Nokia GO wearable step tracker device and end-of-study assessment at the end of the 14-week study period.
Participants will receive the Nokia GO wearable step tracker to monitor daily step counts, but they will not be provided with personalized walking goals or automated feedback on goal attainment via text message.
|
All participants will be provided with a Nokia GO step tracker to monitor daily step counts.
The device is not subject to FDA regulation.
|
|
Experimental: Arm 2 - Intervention arm
Physical activity program supported by financial incentives for meeting walking goals and participating in weekly check-in appointments with study team members via telephone calls.
Participants in the intervention arm will also receive twice-daily medication reminders via bidirectional text messages to promote medication adherence.
Participants in Arm 2 will also receive personalized nutrition and exercise counseling, daily feedback on step counts via the Nokia GO wearable step tracker and their smartphones, and an end-of-study assessment.
|
All participants will be provided with a Nokia GO step tracker to monitor daily step counts.
The device is not subject to FDA regulation.
Medication reminders are sent to participants in Arm 2 on a daily basis.
Virtual meeting or telephone call between participants and study team to assess study involvement, adherence to procedures, and following of medical care recommendations.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of the Intervention
Time Frame: 14 weeks
|
Feasibility of the intervention will be evaluated by the percentage of patients that complete the study intervention.
|
14 weeks
|
|
Acceptability of the Intervention
Time Frame: 14 weeks
|
Acceptability will be measured using a patient satisfaction questionnaire upon study completion.
|
14 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performance on the Short Physical Performance Battery (SPPB)
Time Frame: 14 weeks
|
The SPPB is a simple test to measure lower extremity function using tasks that mimic daily activities.
The SPPB examines three areas of lower extremity function; static balance, gait speed, and getting in and out of a chair.
Static balance is measured in units of time (seconds) and patients are timed holding 3 different stances.
Gait speed is measured in time (seconds) to walk 4 meters.
Chair sits are measured as the time (seconds) it takes to get up and out of a chair 5 times without using one's arms to assist the exercise.
Collectively, the three tests are used to generate a total score (0-12) that reflects a patient's frailty (score of 0) or lack of frailty (score of 12).
|
14 weeks
|
|
Grip strength
Time Frame: 14 weeks
|
Grip strength will be measured using a digital hand dynamometer and the unit of measure is kilograms.
|
14 weeks
|
|
Grip strength level relative to BMI
Time Frame: 14 weeks
|
Body Mass Index (BMI) will be calculated using height in inches and weight in pounds and reported as 'kg/m^2'.
Grip strength will be compared to BMI and a 'BMI-adjusted' grip strength level will be reported using established 'kilogram to BMI ratio' standards.
|
14 weeks
|
|
Body composition/BIA
Time Frame: 14 weeks
|
Bioelectrical impedance analysis will be completed using the Bodystat Quadscan 4000, which is a multi-frequency body composition analyzer.
Body fat percentage (%) will be compared to lean body mass percentage and total body water percentage to assess sarcopenia and nutritional status.
|
14 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Outcomes from Medical Record Review - Liver Transplant listing
Time Frame: 12 months
|
A medical record review will be conducted at the end of the study to review clinical outcomes, liver transplant listing date and occurrence will be assessed.
|
12 months
|
|
Clinical Outcomes from Medical Record Review - Liver Transplantation
Time Frame: 12 months
|
A medical record review will be conducted at the end of the study to review clinical outcomes, date and occurrence liver transplantation will be assessed.
|
12 months
|
|
Clinical Outcomes from Medical Record Review - Death
Time Frame: 12 months
|
A medical record review will be conducted at the end of the study to review clinical outcomes, occurrence and/or date of death will be assessed.
|
12 months
|
|
Clinical Outcomes from Medical Record Review - Hospitalization
Time Frame: 12 months
|
A medical record review will be conducted at the end of the study to review clinical outcomes, number of admissions/hospitalizations will be assessed.
|
12 months
|
|
Clinical Outcomes from Medical Record Review - Removal from Liver Transplant List
Time Frame: 12 months
|
A medical record review will be conducted at the end of the study to review clinical outcomes, occurrence and date of removal from the liver transplant list will be assessed.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 828669
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.